Chris Grace

Pfizer (United Kingdom)

Papers

1

Total Citations

127

H-Index

1

About

Chris Grace is a leading figure in translational bioanalytical chemistry, with a primary focus on developing cutting-edge mass spectrometry-based methods for quantifying protein biomarkers in complex biological matrices. His most cited work, a 2012 paper with 127 citations, exemplifies his major contribution: pioneering sequential protein and peptide immunoaffinity capture techniques. This approach dramatically enhances the sensitivity and specificity of mass spectrometry, enabling the precise quantification of low-abundance proteins like human β-Nerve Growth Factor (NGF). This work was directly instrumental in supporting the clinical development of tanezumab, a monoclonal antibody therapy for chronic pain, by providing a robust method to measure drug-target engagement. Grace’s impact lies in bridging the gap between advanced analytical chemistry and real-world drug development, providing the quantitative tools necessary to validate therapeutic mechanisms. His research has been essential for pharmacokinetic and pharmacodynamic studies, solidifying his reputation as a key innovator in bioanalysis who empowers the translation of novel biologics from bench to bedside.

Research Focus

Key Achievements

1
H-Index
1
Papers
127
Total Citations
127
Avg Citations/Paper
🏆 Most Cited Paper
Sequential Protein and Peptide Immunoaffinity Capture for Mass Spectrometry-Based Quantification of Total Human β-Nerve Growth Factor
127 citations · 2012
📈 Most Prolific Year: 2012 (1 Papers)
🤝 Key Collaborators: 5
🏛 Institutions: Pfizer (United Kingdom)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago